rebaudioside AWhat was measured
Measured, with no finding
32 endpoints
Show what was measuredHide what was measured
mean arterial pressure
no effect, n = 100
Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses
PMID 18555574 · one of two readings recorded this
24-h ambulatory blood pressure responses, device not stated
no effect
Not recorded as a finding: The ambulatory outcome node is systolic-specific and the sentence lumps unspecified 24-h blood pressures; no clean node match
Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses.
PMID 18555574 · one of two readings recorded this
24-h ambulatory blood pressure responses
no effect
Not recorded as a finding: Sentence does not separate systolic from diastolic; the ambulatory node is systolic-only with device and valid-reading requirements the abstract never states
Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses.
PMID 18555574 · one of two readings recorded this
24-h ambulatory blood pressure
no effect, n = 100
Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses
PMID 18555574 · one of two readings recorded this
baseline resting seated DBP
At baseline, mean resting, seated SBP/DBP was 110.0/70.3mmHg and 110.7/71.2mmHg for the rebaudioside A and placebo groups, respectively
PMID 18555574 · one of two readings recorded this
baseline resting seated SBP
At baseline, mean resting, seated SBP/DBP was 110.0/70.3mmHg and 110.7/71.2mmHg for the rebaudioside A and placebo groups, respectively
PMID 18555574 · one of two readings recorded this
heart rate, resting seated, instrument not stated
no effect
Not recorded as a finding: No heart rate outcome node in the list
Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses.
PMID 18555574 · one of two readings recorded this
heart rate
no effect, n = 100
Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses
PMID 18555574 · one of two readings recorded this
resting heart rate (HR)
no effect
Not recorded as a finding: No heart rate outcome node in the list
Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses.
PMID 18555574 · one of two readings recorded this
resting seated diastolic blood pressure
no effect, n = 100
Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses
PMID 18555574 · one of two readings recorded this
resting seated systolic blood pressure
no effect, n = 100
Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses
PMID 18555574 · one of two readings recorded this
blood pressure, body weight and fasting lipids, no instrument stated
no effect
Not recorded as a finding: Sentence is agentless and does not name rebaudioside A, and it groups several endpoints with no estimate
Assessments of changes in blood pressure, body weight, and fasting lipids indicated no differences by treatment.
PMID 18555575 · one of two readings recorded this
blood pressure, body weight and fasting lipids
no effect
Not recorded as a finding: Sentence is agentless (no compound named) and groups several endpoints with no estimate; also lipids not separable to a single node
Assessments of changes in blood pressure, body weight, and fasting lipids indicated no differences by treatment.
PMID 18555575 · one of two readings recorded this
change in blood pressure
no effect
Assessments of changes in blood pressure, body weight, and fasting lipids indicated no differences by treatment
PMID 18555575 · one of two readings recorded this
change in body weight
no effect
Assessments of changes in blood pressure, body weight, and fasting lipids indicated no differences by treatment
PMID 18555575 · one of two readings recorded this
change in C-peptide
no effect
C-peptide (0.13+/-0.09ng/mL and 0.42+/-0.14ng/mL)
PMID 18555575 · one of two readings recorded this
change in fasting glucose
no effect
fasting glucose (7.5+/-3.7mg/dL and 11.2+/-4.5mg/dL)
PMID 18555575 · one of two readings recorded this
change in fasting insulin
no effect
insulin (1.0+/-0.64microU/mL and 3.3+/-1.5microU/mL)
PMID 18555575 · one of two readings recorded this
change in fasting lipids
no effect
Assessments of changes in blood pressure, body weight, and fasting lipids indicated no differences by treatment
PMID 18555575 · one of two readings recorded this
change in glycosylated hemoglobin
no effect, p = 0.355
Mean+/-standard error changes in glycosylated hemoglobin levels did not differ significantly between the rebaudioside A (0.11+/-0.06%) and placebo (0.09+/-0.05%; p=0.355) groups
PMID 18555575 · one of two readings recorded this
hypoglycemic episodes
no effect
Rebaudioside A was well-tolerated, and records of hypoglycemic episodes showed no excess vs. placebo
PMID 18555575 · one of two readings recorded this
plasma steviol glucuronide Cmax and AUC0-t, tmax and t1/2, and urinary excretion after single oral rebaudioside A versus stevioside
decreases, steviol glucuronide geometric mean Cmax approximately 22% lower after rebaudioside A (1472 ng/mL) than after stevioside (1886 ng/mL)
Not recorded as a finding: the comparison was against another active treatment
Administration of rebaudioside A resulted in a significantly (approximately 22%) lower steviol glucuronide geometric mean Cmax value (1472ng/mL) than administration of stevioside (1886ng/mL).
PMID 18555578 · one of two readings recorded this
steviol glucuronide geometric mean AUC0-t
decreases
The geometric mean AUC0-t value for steviol glucuronide after administration of rebaudioside A (30,788ngh/mL) was approximately 10% lower than after administration of stevioside (34,090ngh/mL)
PMID 18555578 · one of two readings recorded this
steviol glucuronide geometric mean Cmax
decreases
Administration of rebaudioside A resulted in a significantly (approximately 22%) lower steviol glucuronide geometric mean Cmax value (1472ng/mL) than administration of stevioside (1886ng/mL)
PMID 18555578 · one of two readings recorded this
steviol glucuronide plasma Cmax, AUC0-t, tmax and half-life, and urinary and faecal excretion, after single oral doses of rebaudioside A versus stevioside
decreases, approximately 22% lower steviol glucuronide geometric mean Cmax (1472 vs 1886 ng/mL) after rebaudioside A than after stevioside
Not recorded as a finding: the comparison was against another active treatment
Administration of rebaudioside A resulted in a significantly (approximately 22%) lower steviol glucuronide geometric mean Cmax value (1472ng/mL) than administration of stevioside (1886ng/mL).
PMID 18555578 · one of two readings recorded this
AUC blood glucose 0-2 h during OGTT
no effect, n = 30
Rebaudioside A administration did not result in lower glycemia nor higher insulin or C-peptide concentrations compared to placebo, neither in the fasting state nor during the OGTT
PMID 36057030 · one of two readings recorded this
AUC of blood glucose during a 75 g OGTT 19 h after dosing (AUCGlucose(0-2h)), with insulin and C-peptide concentrations and maximal glucose
no effect
Not recorded as a finding: the supporting sentence never names the compound
The AUCs, glucose excursion and maximal glucose, insulin and C-peptide concentrations were also comparable for all these parameters in both conditions (and Table S2 of the Supplementary Information).
PMID 36057030 · one of two readings recorded this
blood glucose, insulin and C-peptide AUCs, glucose excursion and maximal concentrations during a 75 g OGTT 19 h after a single 3 g dose, hexokinase method
no effect
Not recorded as a finding: the supporting sentence never names the compound
The AUCs, glucose excursion and maximal glucose, insulin and C-peptide concentrations were also comparable for all these parameters in both conditions (and Table S2 of the Supplementary Information).
PMID 36057030 · one of two readings recorded this
fasting-state glycemia, insulin and C-peptide
no effect, n = 30
Rebaudioside A administration did not result in lower glycemia nor higher insulin or C-peptide concentrations compared to placebo, neither in the fasting state nor during the OGTT
PMID 36057030 · one of two readings recorded this
glucose excursion and maximal glucose, insulin and C-peptide concentrations
no effect, n = 30
The AUCs, glucose excursion and maximal glucose, insulin and C-peptide concentrations were also comparable for all these parameters in both conditions
PMID 36057030 · one of two readings recorded this
serum C-peptide during OGTT
no effect, n = 30
Rebaudioside A administration did not result in lower glycemia nor higher insulin or C-peptide concentrations compared to placebo, neither in the fasting state nor during the OGTT
PMID 36057030 · one of two readings recorded this
serum insulin during OGTT
no effect, n = 30
Rebaudioside A administration did not result in lower glycemia nor higher insulin or C-peptide concentrations compared to placebo, neither in the fasting state nor during the OGTT
PMID 36057030 · one of two readings recorded this